Leading Experts in Cancer Care and Research

NewYork-Presbyterian at ASCO 2017

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology (ASCO) annual meeting. As world leaders in cancer care spanning treatments for all types of cancer, we will be presenting on clinical trials with an emphasis on precision medicine and immunotherapies. Please follow along with us on Twitter at @nyphospital for details on presentations, physician commentary and related resources.

asco graphic

Click here for the high-res image.

Hi-Tech Blood Biomarker Signals When a Strategic Switch in Chemotherapy Will Benefit Prostate Cancer Patients

For men with metastatic prostate cancer that grows despite hormonal therapy (also referred to as castration-resistant prostate cancer), chemotherapy has been a mainstay. The class of chemotherapy that has consistently proved to improve survival for men with advanced prostate cancer is called “taxanes.”

Read more »

Meet the Girl with Gene NUP214-ABL1

When Myrrah Shapoo arrived at NewYork-Presbyterian/Columbia University Medical Center last year with a form of cancer that wouldn’t respond to chemotherapy, a team of physicians and scientists working on a new precision-medicine initiative faced their ultimate test.

Read more »

ASCO 2016 – Myeloma Update

In myeloma, there are numerous choices for therapy. We recommend treatments based on the risk level of the disease. Patients are divided into two groups, standard risk and high risk. In most centers, risk categorization is an important consideration when deciding the best course of treatment. Assessing risk typically involves the underlying health and age of the patient, the extent of disease, and genetic abnormalities within the cells. The standard system to classify extent or "stage" is called the International Staging System or “ISS.” The standard method to assess genetic abnormalities is called FISH (fluorescent in situ hybridization).

Read more »

Biomarker Confirms Efficacy of Early Drug Switch for Prostate Cancer Patients

Metastatic prostate cancer patients respond better to treatment when they switch to different drugs in the absence of an optimal initial response, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.

Read more »

Innovative Immunotherapy More Effective in Treating an Aggressive Lymphoma than Chemotherapy

A drug that recruits immune cells to fight an aggressive form of lymphoma that disproportionately affects minorities in the United States appears to be more effective than chemotherapy, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.

Read more »

ASCO 2016: Updates in Advanced Prostate Cancer and Precision Medicine

Advances in therapeutics have led to improvements in both survival and quality of life for patients with cancer, including men with advanced prostate cancer. Simultaneously, a number of cutting-edge scientific advances have been made in the underlying biology of advanced prostate cancer. There is great potential and power in integrating these new therapeutics and biomarkers, which is often referred to precision medicine. While great advances have already been made in this area, many remain highly sophisticated and restricted to selected centers, such as Weill Cornell Medicine and NewYork-Presbyterian Hospital, while others still need validation in a larger number of patients. Ultimately, the goal is to be able to bring these technologies and treatments to cancer patients all around the country and the world.

Read more »

Prostate Cancer Treatment: Getting the Best Results by Targeting the Right Cells at the Right Time

Lutetium 177 (also known as Lu-177 or 177-Lu) is a very popular radioactive particle used to treat prostate cancer in Europe, as it has previously been shown to be effective against metastatic prostate cancer. For more than 10 years, Weill Cornell Medicine has been one of very few centers in the United States that is able to offer this as a targeted prostate cancer treatment.

Read more »

Use of Complementary and Alternative Medicine Affects Breast Cancer Chemotherapy Initiation

Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND, PhD, Associate Professor of Epidemiology at Columbia University's Mailman School of Public Health.

Read more »

Dr. Dawn Hershman recognized in ASCO’s 2016 Recipients of FASCO Distinction

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO.

Read more »

What the gut? Two studies explore microbiome-cancer connection

How do the bacteria swimming inside and around our guts change our chances of developing cancer? What effect might they have on the immune system? And what happens when you introduce antibiotics or anti-inflammatory drugs?

Read more »

Immunotherapy: New Hope for Patients with Advanced Lung Cancer

In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an infection after undergoing surgery.

Read more »

What a simple blood test can reveal about chemo and prostate cancer

From our personalities to our hair and eye colors, genetic variations make us who we are. When it comes to cancer, genetic variations can also share insights into who is most likely or least likely to respond to a particular treatment.

Read more »

For Adults with Common Form of Leukemia, New Drug Promises Fewer Side Effects

In phase I/II trial, new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears as effective as ibrutinib with fewer side effects.

Read more »

The treatment paradigm for gastrointestinal cancers

BBI608 is currently under investigation via the phase III BRIGHTER trial as a second-line treatment for patients with gastric and gastroesophageal junction cancer who have previously undergone platinum and fluoropyrimidine-based chemotherapy.

Read more »

Disparities in Breast Cancer Care Linked to Net Worth

Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.

Read more »

Targeting cancer stem cells in the BRIGHTER trial

Napabucasin, a novel oral agent that targets the STAT3 pathway, is the most advanced new drug in clinical development designed specifically to attack cancer stem cells (CSCs), a subset of the total cancer cell population that is believed to drive tumor recurrence and metastasis even after cytotoxic therapy.

Read more » | Read additional coverage in OncLive »

Programs to Improve Diets May Miss a Cultural Ingredient

In the United States, low-income ethnic minorities are more likely to be obese and thus at risk for a variety of chronic illnesses, compared with white Americans.

Read more »

Weill Cornell researchers create device to collect living prostate tumor cells

Cancer metastases (spreading from the initial cancer tumor to other parts of the body) account for the majority of cancer-related deaths because of poor responses to anti-cancer therapies. Researchers at Weill Cornell Medical College, in collaboration with engineers from Cornell University in Ithaca, NY, have created a new device that searches the blood for living, circulating tumor cells.

Read more »

A Columbia Oncologist Explains Immunotherapy

At Columbia’s March 24 event on the future of cancer research, Gary Schwartz, MD, professor of medicine and chief of the division of hematology-oncology at Columbia, explained the new field of immunotherapy.

Read more »